Meiji Yasuda Life Insurance Co Reduces Stock Position in Boston Scientific Corporation $BSX

Meiji Yasuda Life Insurance Co cut its holdings in Boston Scientific Corporation (NYSE:BSX) by 53.6% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 14,895 shares of the medical equipment provider’s stock after selling 17,174 shares during the period. Meiji Yasuda Life Insurance Co’s holdings in Boston Scientific were worth $636,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of BSX. Brighton Jones LLC lifted its position in shares of Boston Scientific by 0.8% during the fourth quarter. Brighton Jones LLC now owns 27,376 shares of the medical equipment provider’s stock worth $2,445,000 after acquiring an additional 226 shares in the last quarter. FWL Investment Management LLC purchased a new position in shares of Boston Scientific in the second quarter valued at $26,000. Main Street Financial Solutions LLC grew its position in shares of Boston Scientific by 35.3% in the second quarter. Main Street Financial Solutions LLC now owns 7,556 shares of the medical equipment provider’s stock valued at $812,000 after purchasing an additional 1,971 shares in the last quarter. Ieq Capital LLC raised its stake in shares of Boston Scientific by 97.0% during the 2nd quarter. Ieq Capital LLC now owns 123,592 shares of the medical equipment provider’s stock valued at $13,275,000 after purchasing an additional 60,860 shares during the period. Finally, HUB Investment Partners LLC lifted its holdings in Boston Scientific by 56.2% during the 2nd quarter. HUB Investment Partners LLC now owns 7,102 shares of the medical equipment provider’s stock worth $763,000 after purchasing an additional 2,556 shares in the last quarter. Institutional investors own 89.07% of the company’s stock.

Boston Scientific Trading Down 0.0%

Shares of Boston Scientific stock opened at $46.82 on Monday. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.24 and a quick ratio of 0.74. Boston Scientific Corporation has a 1 year low of $42.20 and a 1 year high of $109.50. The firm has a market cap of $67.85 billion, a PE ratio of 18.96, a PEG ratio of 1.02 and a beta of 0.56. The company has a 50 day simple moving average of $46.56 and a two-hundred day simple moving average of $56.53.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 EPS for the quarter, topping analysts’ consensus estimates of $0.83 by $0.03. The firm had revenue of $5.44 billion for the quarter, compared to analyst estimates of $5.38 billion. Boston Scientific had a net margin of 17.50% and a return on equity of 19.28%. The business’s revenue for the quarter was up 7.5% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.75 EPS. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. Analysts expect that Boston Scientific Corporation will post 3.3 earnings per share for the current fiscal year.

Boston Scientific announced that its board has authorized a stock repurchase program on Monday, May 18th that allows the company to repurchase $5.00 billion in shares. This repurchase authorization allows the medical equipment provider to repurchase up to 6.4% of its shares through open market purchases. Shares repurchase programs are usually a sign that the company’s leadership believes its stock is undervalued.

Wall Street Analyst Weigh In

Several brokerages have commented on BSX. Oppenheimer cut their target price on Boston Scientific from $90.00 to $85.00 and set an “outperform” rating for the company in a research note on Monday, July 27th. Weiss Ratings downgraded shares of Boston Scientific from a “hold (c-)” rating to a “sell (d+)” rating in a report on Tuesday, July 7th. Bank of America cut their price objective on shares of Boston Scientific from $105.00 to $68.00 and set a “buy” rating for the company in a research report on Monday, May 18th. Royal Bank Of Canada decreased their target price on shares of Boston Scientific from $85.00 to $70.00 and set an “outperform” rating on the stock in a report on Thursday, July 30th. Finally, TD Cowen reiterated a “buy” rating and issued a $56.00 target price on shares of Boston Scientific in a research note on Tuesday, August 25th. Twenty-four research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $71.62.

Insider Activity at Boston Scientific

In other news, Director Edward J. Ludwig purchased 5,000 shares of the stock in a transaction on Friday, July 31st. The shares were acquired at an average price of $45.48 per share, for a total transaction of $227,400.00. Following the completion of the transaction, the director directly owned 30,359 shares of the company’s stock, valued at approximately $1,380,727.32. This trade represents a 19.72% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this link. Also, CEO Michael F. Mahoney acquired 186,240 shares of Boston Scientific stock in a transaction dated Monday, August 3rd. The shares were purchased at an average price of $48.33 per share, for a total transaction of $9,000,979.20. Following the completion of the transaction, the chief executive officer directly owned 1,590,024 shares in the company, valued at approximately $76,845,859.92. The trade was a 13.27% increase in their position. The SEC filing for this purchase provides additional information. Insiders have bought a total of 194,522 shares of company stock valued at $9,385,210 over the last 90 days. 0.34% of the stock is owned by insiders.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.